SPY408.32+8.23 2.06%
DIA327.10+4.32 1.34%
IXIC11,984.52+321.73 2.76%

Lyra Therapeutics Highlights Presentation Of Data From LANTERN Phase 2 Study Of LYR-210 For Treatment Of Chronic Rhinosinusitis At Combined Otolaryngology Spring Meetings Apr. 27-May 1

LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to control LYR-210 may

Benzinga · 04/29/2022 09:08

LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients

LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to control

LYR-210 may improve mental and physical health and quality of life of CRS patients

WATERTOWN, Mass., April 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today is presenting additional, new data from its LANTERN Phase 2 study of LYR-210 in adult patients with chronic rhinosinusitis (CRS) at the 2022 Combined Otolaryngology Spring Meetings (COSM) being held April 27 – May 1, 2022 in Dallas, Texas. LYR-210 is designed as an alternative to sinus surgery for the millions of CRS patients that remain symptomatic despite treatment.

Anders Cervin, MD, PhD, Professor Chair in Otolaryngology at the Centre for Clinical Research, Royal Brisbane & Women's Hospital Campus, Herston, in Queensland Australia, and an investigator in the LANTERN study, is presenting the data.

"These positive data build on the LANTERN Phase 2 results supporting our belief in LYR-210's meaningful improvement of patients' CRS symptoms and quality of life," said Dr. Cervin. "Using the SNOT-22 score, a validated tool for assessing patients' symptoms and guiding their treatment, we were pleased to see that LYR-210 drove improvements in all five SNOT-22 sub-domains as well as the SF-36, a widely used clinical measure of quality of life."

"These encouraging LANTERN data demonstrate the potential of LYR-210 to transform the treatment paradigm for CRS patients who still experience debilitating symptoms with current treatment approaches," said Robert Kern, MD, Chief Medical Officer of Lyra Therapeutics. "We look forward to further advancing LYR-210 through the clinic in the ENLIGHTEN Phase 3 program, which was initiated earlier this year."

Summary of Data Presented

Impact of long-acting implantable corticosteroid matrices on SNOT-22 subdomains in CRS patients: selected as COSM 2022 top-rated clinical abstract by the American Rhinologic Society

The 22-item sino-nasal outcome test (SNOT-22) is a validated and routinely used CRS-specific quality of life questionnaire consisting of five subdomains: rhinologic, extra-nasal rhinologic, ear/facial, psychological dysfunction, and sleep dysfunction. Higher scores indicate higher severity of symptoms and/or social and emotional consequences.

Key results include:

  • LYR-210 (7500μg)-treated subjects reported dose-dependent global symptom improvement, achieving statistical significance (p<0.05) in each SNOT-22 subdomain compared to control at week 24.
  • LYR-210 (7500μg)-treated subjects reported decreased rhinologic, ear/facial, extra-nasal rhinologic, psychological dysfunction, and sleep dysfunction domain scores by an average of 10.0, 8.0, 5.2, 15.2, and 10.3 points from baseline, respectively.
  • LYR-210 (7500µg)-treated subjects reported more than twice the minimal clinically important difference in each SNOT-22 subdomain at week 24.

These results are supportive of the previously reported, statistically significant 19-point improvement for LYR-210 (7500µg) over control in SNOT-22 total score at week 24.

Quality of life in CRS patients treated with long-acting implantable corticosteroid matrices

The 36-item short-form health survey, version 2 (SF-36v2) is a validated, non-disease specific, and frequently used patient-reported outcome instrument to measure physical and mental health in clinical trials.

Key results include:

  • LYR-210 (7500μg)-treated subjects reported a statistically significant improvement at week 24 in the Mental Component Summary, vitality, social functioning, role-emotional, and mental health scores compared to control.
  • LYR-210 (7500μg)-treated subjects reported statistically significant improvement at week 24 in the physical functioning, role-physical, and bodily pain scores, compared to control.
  • At week 24, the mean change from baseline for LYR-210 (7500ug)-treated subjects met the threshold for clinical meaningfulness compared to control in the Mental Component Summary and all individual scales except general health.

These data suggest that LYR-210 (7500μg) may improve the mental and physical health and quality of life of CRS patients.